Literature DB >> 22007611

Re-evaluation of 400 Crimean-Congo hemorrhagic fever cases in an endemic area: is ribavirin treatment suitable?

Fazilet Duygu1, Turan Kaya, Pinar Baysan.   

Abstract

BACKGROUND: Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne viral disease, seen in various regions around the world, leading to death following a clinical syndrome of hemorrhagic fever.
METHODS: This trial was conducted in Tokat State Hospital that is located in an endemic area. Four hundred patients referring to hospital between 2007 and 2009 and diagnosed as having CCHF with RT-PCR were enrolled in this trial. Ribavirin was not administered to any patient. Epidemiological, clinical, and laboratory findings of CCHF and factors affecting mortality were evaluated.
RESULTS: Twenty patients (5%) died and 380 patients recovered (95%). It was found that mean age, white blood cells (WBC), active tromboplastine time (aPTT), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) values were significantly higher in patients who died, as compared with recovered cases and the difference was significant. Platelet values were significantly lower in patients who died, as compared with recovered cases.
CONCLUSIONS: Age, male gender, high levels of ALT, AST, WBC aPTT values, platelet levels, and decrease in these values during follow-up are indicative of a poor prognosis. Use of ribavirin is not required in treatment of CCHF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22007611     DOI: 10.1089/vbz.2011.0694

Source DB:  PubMed          Journal:  Vector Borne Zoonotic Dis        ISSN: 1530-3667            Impact factor:   2.133


  8 in total

Review 1.  Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies.

Authors:  Brian B Gowen; Brady T Hickerson
Journal:  J Microbiol       Date:  2017-02-28       Impact factor: 3.422

2.  Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus.

Authors:  Marko Zivcec; Lisa I W Guerrero; César G Albariño; Éric Bergeron; Stuart T Nichol; Christina F Spiropoulou
Journal:  Antiviral Res       Date:  2017-08-24       Impact factor: 5.970

Review 3.  Crimean-Congo hemorrhagic fever: an overview.

Authors:  Serkan Oncü
Journal:  Virol Sin       Date:  2013-07-22       Impact factor: 4.327

4.  Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever.

Authors:  Lisa Oestereich; Toni Rieger; Melanie Neumann; Christian Bernreuther; Maria Lehmann; Susanne Krasemann; Stephanie Wurr; Petra Emmerich; Xavier de Lamballerie; Stephan Ölschläger; Stephan Günther
Journal:  PLoS Negl Trop Dis       Date:  2014-05-01

Review 5.  Tick-Borne Viruses.

Authors:  Junming Shi; Zhihong Hu; Fei Deng; Shu Shen
Journal:  Virol Sin       Date:  2018-03-13       Impact factor: 4.327

6.  Development of Multi-epitope Based Subunit Vaccine Against Crimean-Congo Hemorrhagic Fever Virus Using Reverse Vaccinology Approach.

Authors:  Md Ashik Imran; Md Rubiath Islam; Akash Saha; Shahida Ferdousee; Moshiul Alam Mishu; Ajit Ghosh
Journal:  Int J Pept Res Ther       Date:  2022-06-24       Impact factor: 2.191

Review 7.  Molecular Insights into Crimean-Congo Hemorrhagic Fever Virus.

Authors:  Marko Zivcec; Florine E M Scholte; Christina F Spiropoulou; Jessica R Spengler; Éric Bergeron
Journal:  Viruses       Date:  2016-04-21       Impact factor: 5.048

8.  Ribavirin is not effective against Crimean-Congo hemorrhagic fever: observations from the Turkish experience.

Authors:  Bahadır Ceylan; Aylin Calıca; Oznur Ak; Yasemin Akkoyunlu; Vedat Turhan
Journal:  Int J Infect Dis       Date:  2013-06-15       Impact factor: 3.623

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.